Forms of dolasetron mesylate and processes for their preparation
The present invention provides crystalline polymorphic forms of Dolasetron mesylate. Also provided are methods of preparing the crystalline polymorphic forms of Dolasetron mesylate. Further, the crystalline Dolasetron mesylate forms may be used in pharmaceutical compositions.
The present application claims the benefit of the following U.S. Provisional Patent Application Nos.: 60/756,690, filed Jan. 5, 2006; 60/800,884, filed May 15, 2006; 60/838,758, filed Aug. 17, 2006; 60/861,354, filed Nov. 27, 2006; 60/802,842, filed May 22, 2006; 60/818,934, filed Jul. 5, 2006; 60/833,515, filed Jul. 24, 2006; 60/836,432, filed Aug. 7, 2006; 60/763,683, filed Jan. 30, 2006; 60/784,248, filed Mar. 20, 2006; 60/815,199, filed Jun. 19, 2006; 60/852,887, filed Oct. 18, 2006. The contents of these applications are incorporated herein by reference.
FIELD OF THE INVENTIONThe present invention encompasses the solid state chemistry of Dolasetron Mesylate.
BACKGROUND OF THE INVENTION Dolasetron mesylate monohydrate, (2α,6α,8α,9αβ)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate monomethanesulfonate monohydrate (referred to as DLS-MsOH.H2O) a compound having the chemical structure,
Dolasetron Mesylate monohydrate is a serotonin receptor (5-HT3) antagonist used as an antiemetic and antinauseant agent in chemo- and radiotherapies.
Dolasetron mesylate (DLS-MsOH) developed by Merrell Dow Pharmaceuticals is marketed as tablets for oral administration and as sterile solution for intravenous administration by Aventis, under the name Anzemet®.
EP patent No. 0339669 describes the crystallization of DLS-MsOH.H2O (monohydrate) from an aqueous isopropanol-ether mixture.
EP patent No. 0266730 describes the crystallization of DLS-MsOH.
The present invention relates to the solid state physical properties of Dolasetron mesylate. These properties can be influenced by controlling the conditions under which Dolasetron mesylate is obtained in solid form. Solid state physical properties include, for example, the flowability of the milled solid. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.
Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid. The rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream. The rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments. The solid state form of a compound may also affect its behavior on compaction and its storage stability.
These practical physical characteristics are influenced by the conformation and orientation of molecules in the unit cell, which defines a particular polymorphic form of a substance that can be identified unequivocally by X-ray spectroscopy. The polymorphic form may give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others. A particular polymorphic form may also give rise to distinct spectroscopic properties that may be detectable by solid state 13C NMR spectrometry and infrared spectroscopy.
The present invention also relates to solvates of Dolasetron mesylate. When a substance crystallizes out of solution, it may trap molecules of solvent at regular intervals in the crystal lattice. Solvation also affects utilitarian physical properties of the solid state like flowability and dissolution rate.
One of the most important physical properties of a pharmaceutical compound, which can form polymorphs or solvates, is its solubility in aqueous solution, particularly the solubility in gastric juices of a patient. Other important properties relate to the ease of processing the form into pharmaceutical dosages, as the tendency of a powdered or granulated form to flow and the surface properties that determine whether crystals of the form will adhere to each other when compacted into a tablet.
The discovery of new polymorphic forms and solvates of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.
SUMMARY OF THE INVENTIONIn one embodiment, the present invention encompasses a crystalline form of Dolasetron Mesylate characterized by a powder XRD pattern with peaks at about 12.6, 18.2, and 19.6±0.2 degrees two-theta.
In another embodiment the present invention encompasses an amorphous form of Dolasetron mesylate.
In yet another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 14.0, 14.8, 16.1, and 18.2±0.2 degrees 2-theta.
In one embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 13.8, 16.5, 22.1, and 25.2±0.2 degrees 2-theta.
In another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 13.0, 18.6 and 29.4±0.2 degrees 2-theta.
In yet another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.9, 15.2, and 16.0±0.2 degrees 2-theta.
In one embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 10.1, 16.3, and 22.6±0.2 degrees 2-theta.
In another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.8, 18.3, and 27.9±0.2 degrees 2-theta.
In yet another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.4, 17.7 and 27.1±0.2 degrees 2-theta.
In one embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 14.1, 14.9, 16.2 and 18.2±0.2 degrees 2-theta.
In another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 14.7, 17.6 and 18.2±0.2 degrees 2-theta.
In yet another embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.1, 15.0 and 18.1±0.2 degrees 2-theta.
In one embodiment the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 17.4, 17.9 and 22.1±0.2 degrees 2-theta.
In another embodiment, the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 12.2, 14.1, 14.8, 16.3 and 22.2±0.2 degrees 2-theta.
In yet another embodiment, the present invention encompasses a crystalline form of Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 12.1, 14.0, 14.8 15.1 and 22.1±0.2 degrees 2-theta.
In one embodiment, the present invention also provides an alcoholate solvate of Dolasetron mesylate.
In another embodiment, the present invention provides an anhydrous Dolasetron mesylate.
In yet another embodiment, the present invention also provides a ketone solvate of Dolasetron mesylate.
In another embodiment, the present invention provides a carbonate solvate of Dolasetron mesylate.
In another embodiment, the present invention also provides an ether solvate of Dolasetron mesylate.
In another embodiment, the present invention provides an ester solvate of Dolasetron mesylate.
In another embodiment, the present invention also provides a nitromethane solvate of Dolasetron mesylate.
In another embodiment, the present invention also provides a hydrated Dolasetron mesylate.
In one embodiment, the present invention encompasses a process for preparing a crystalline form of Dolasetron mesylate, designated form II, comprising combining Dolasetron base, methanesulfonic acid, and a solvent mixture comprising acetone, and water.
In yet another embodiment, the present invention comprises a pharmaceutical composition comprising at least one of the above forms of Dolasetron Mesylate, and at least one pharmaceutically acceptable excipient.
In yet another embodiment, the present invention comprises a pharmaceutical composition comprising at least one of the above forms of Dolasetron Mesylate prepared according to the processes of the present invention, and at least one pharmaceutically acceptable excipient.
In one embodiment, the present invention further encompasses a process for preparing a pharmaceutical formulation comprising combining at least one of the above forms of Dolasetron Mesylate with at least one pharmaceutically acceptable excipient.
In another embodiment, the present invention comprises a process for preparing a pharmaceutical composition comprising at least one of the above forms of Dolasetron Mesylate, prepared according to the processes of the present invention, and at least one pharmaceutically acceptable excipient.
In yet another embodiment, the present invention further encompasses the use of at least one of the above forms of Dolasetron Mesylate, for the manufacture of a pharmaceutical composition.
BRIEF DESCRIPTION OF THE FIGURES
As used herein, the term “anhydrous” refers to a substance that contains no more than 1%, preferably no more than 0.6%, by weight of water or of any solvent.
As used herein the term “room temperature” refers to a temperature of about 20° C. to about 30° C.
The EP 0339699 describes preparing a crystalline Dolasetron mesylate. This crystalline Dolasetron mesylate is designated herein as crystalline form II of Dolasetron mesylate. The crystalline form II of Dolasetron mesylate is characterized by a powder XRD pattern of with peaks at about 12.1, 12.9, 15.1, and 22.4±0.2 degrees two-theta. The crystalline form II may be further characterized by a powder X-ray diffraction pattern with peaks at about 9.9, 17.0, 19.0, 19.7, 20.0, and 26.4±0.2 degrees two-theta
The present invention encompasses a crystalline form of Dolasetron Mesylate, designated form I, characterized by a powder XRD pattern with peaks at about 12.6, 18.2, and 19.6±0.2 degrees two-theta. The crystalline form may be further characterized by a powder X-ray diffraction pattern with peaks at about 9.9, 13.8, 16.6, 21.1, 23.3, 27.9, and 29.6±0.2 degrees two-theta. The crystalline form may also be substantially identified by the PXRD pattern as depicted in
The above crystalline form is a solvated form of Dolasetron mesylate; preferably, an alcoholate, more preferably, ethanolate, most preferably, hemiethanolate.
The said crystalline form I of Dolasetron Mesylate comprises less than about 10% of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form I of Dolasetron Mesylate comprises less than about 10%, preferably less than about 5%, more preferably less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD
The present invention further encompasses a process for preparing the crystalline form of Dolasetron Mesylate, designated form I, by a process comprising combining Dolasetron base, ethanol and methanesulfonic acid to obtain Dolasetron mesylate; and crystallizing it from a mixture of acetone and tert-butylmethyl ether.
Dolasetron base may be prepared, for example, according to the process disclosed in European Patent No. 0339699. Dolasetron base may also be prepared by a process comprising the steps of a) combining a CCA-ester of formula III,
an oxidizing agent selected from the group consisting of: hydroperoxides, dialkyl peroxides, peroxyacids, peroxyesters, diacyl peroxides, persulphate, perborate and perphosphate, a catalyst and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, to form CCA-epoxide; b) admixing CCA-epoxide with an oxidizing agent, and a solvent selected from the group consisting of water and a water miscible organic solvent; c) raising the pH; d) admixing with a pH 4 buffer, a glycine C1-4 ester or salts thereof, and a substance comprising a carbonyl moiety selected from the group consisting of 1,3 acetonedicarboxylic acids, acetone and a C1-4 ester thereof, e) admixing with a reducing agent, and a solvent selected from the group consisting of water, water miscible organic solvents and mixtures thereof, f) admixing with a silylating agent selected from a group consisting of: silanes, silyl halogenides, silyl cyanides, silyl amines, silyl amides, silyl trifluoromethanesulfonates (silyl triflates), and silazanes, a base, and an aprotic organic solvent to form a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compound (a SAN compound); g) admixing with a metal alkoxide, and a polar a-protic organic solvent to form a reaction mixture; h) heating the reaction mixture; i) quenching with a with a weak acid selected from the group consisting of acetic acid, formic acid, acetic acid, propionic acid, maleic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, citric acid, mandelic acid, benzoic acid, and salicylic acid forming an endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one (trans-hexahydro-4-alkoxycarbonyl-8-trialkylsilyloxy-2,6-methano-2H-quinolizin-3(4H)-one) compound (referred to as a SQO compound); j) admixing with a solvent selected from a group consisting of: water, and water-immiscble organic solvent, and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, fluoroboric acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid, naphthalene sulfonic and disulfonic acids; k) admixing with an anhydride, 3-indole carboxylic acid, a halogenated hydrocarbon, and a catalyst to obtain Dolasetron base. In this process the silylating reagents in step f) can be replaced be reagents comprising an ether protecting group forming a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-[(tetrahydro-2H-pyran2-yl)oxy]-9-azabicyclo[3.3.1]nonane intermediate (referred to as a PAN intermediate) or with an acylating agent forming a 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-acyloxy-9-azabicyclo[3.3.1]nonane intermediate (a PivAN intermediate). When a PivAN intermediate is prepared steps g), h), and i) are omitted.
Dolasetron mesylate is preferably provided by dissolving Dolasetron base in a C1-4 alcohol, preferably ethanol followed by admixing the solution with methanesulfonic acid to obtain a second solution comprising Dolasetron mesylate. Preferably, the Dolasetron base is dissolved in the C1-4 alcohol, preferably ethanol, at about room temperature, more preferably, at about 20° C. to about 25° C.
Preferably, prior to the crystallization, the second solution is concentrated to obtain residue.
Preferably, the crystallization is done by a process comprising providing a solution of the residue of Dolasetron Mesylate in a mixture comprising acetone and tert-butylmethyl ether, and precipitating the crystalline form to obtain a suspension.
Preferably, precipitation is done by cooling the solution to a temperature of about −5° C. to about 10° C., preferably to a temperature of about 0° C. to about 10° C., more preferably, to a temperature of about 2° C. to about 8° C. Preferably, the solution is cooled for at least about 12 hours, more preferably for at least 6 hours.
The process may further comprise recovering the said crystalline form. The recover may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, washing the filtered crystalline form, and drying it.
The present invention also encompasses an amorphous form of Dolasetron mesylate, designated Form VII. The amorphous form of Dolasetron mesylate may be substantially identified by the PXRD pattern as depicted in
The said amorphous form of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said amorphous form of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, with less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention encompasses a process for the preparation of the amorphous form of Dolasetron mesylate, designated form VII, comprising combining Dolasetron mesylate and methanol, and removing the methanol.
The starting Dolasetron mesylate may be any form of Dolasetron mesylate, preferably, the Dolasetron mesylate monohydrate. Preferably, the starting Dolasetron mesylate is dissolved in methanol, at about 15° C. to about 35° C., preferably about room temperature, more preferably, at about 20° C. to about 25° C. Preferably, methanol, is removed by evaporation of the solution Preferably, evaporation is done under reduced pressure. Preferably, the solvent is removed to dryness.
The present invention further provides an additional process for preparing the amorphous form by heating a Dolasetron mesylate polymorph selected from the group consisting of: crystalline form I of Dolasetron mesylate, crystalline form II of Dolasetron mesylate, crystalline form IV of Dolasetron mesylate, crystalline form VI of Dolasetron mesylate, crystalline form IX of Dolasetron mesylate, crystalline form X of Dolasetron mesylate, crystalline form XIII of Dolasetron mesylate, crystalline form XIV of Dolasetron mesylate, and mixtures thereof to a temperature of at least 160° C., for at least 15 minutes, preferably at least 30 minutes.
Preferably, the starting Dolasetron mesylate forms are heated to a temperature of about 160° C. to about 200° C., more preferably to a temperature of about 160° C. to about 190° C. Preferably, the heating is done for about 30 to about 70 minutes, more preferably, for about 60 minutes.
The present invention further encompasses a crystalline form of Dolasetron mesylate, designated Form III, characterized by a powder XRD pattern with peaks at about 14.0, 14.8, 16.1, and 18.2±0.2 degrees 2-theta. Form III may be further characterized by a powder XRD with peaks at about 9.2, 12.2, 20.9, 27.9, 29.0, and 29.6±0.2 degrees 2-theta. Form III may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form III of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form III of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention also encompasses a process for the preparation of Form III of Dolasetron mesylate comprising crystallizing Dolasetron mesylate from t-butanol.
The crystallization comprises providing a solution of Dolasetron mesylate in t-butanol and precipitating the said crystalline form to obtain a suspension.
The solution of Dolasetron mesylate is preferably provided by combining Dolasetron mesylate and t-butanol, and heating the mixture. Preferably, heating is to at a temperature of about 70° C. to about 85° C., preferably about 80° C. to about 85° C.
The Dolasetron mesylate starting material can be any form of Dolasetron mesylate, preferably, the Dolasetron mesylate monohydrate.
Preferably, precipitation of the crystalline form is carried out by cooling the solution to about 15° C. to about 35° C., preferably to about room temperature, more preferably, to about 20° C. to about 25° C.
Further, the cooled solution is preferably maintained at such temperature to increase the yield of the precipitated crystalline form. Preferably, the cooled solution is maintained at such temperature for a period of about 0.5 to about 5 days, more preferably for about 1 to 4 days, most preferably for 3 days.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention further provides an additional process for preparing the said Form III by heating a Dolasetron mesylate polymorph selected from the group consisting of: amorphous form of Dolasetron mesylate, crystalline Form I of Dolasetron mesylate, crystalline form XI of Dolasetron mesylate, and mixtures thereof, to a temperature of no more than 160° C., for no more than 60 minutes.
Preferably, the starting polymorph of Dolasetron mesylate is heated to a temperature of about 160° C. Preferably, the heating is done for about 30 minutes.
The present invention encompasses a crystalline form of Dolasetron mesylate, designated Form IV, characterized by a powder XRD pattern with peaks at about 13.8, 16.5, 22.1, and 25.2±0.2 degrees 2-theta. Form IV may be further characterized by a powder XRD with peaks at about 9.7, 12.5, 18.0, 19.4, 20.7, and 27.5±0.2 degrees 2-theta. Form IV may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form IV of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other forms of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form IV of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention further encompasses a process for the preparation of Form IV of Dolasetron mesylate comprising combining Dolasetron mesylate and ethanol, preferably absolute ethanol, and removing the ethanol.
The starting Dolasetron mesylate can be any form of Dolasetron mesylate, preferably, Dolasetron mesylate monohydrate.
Preferably, the starting Dolasetron mesylate is dissolved in ethanol at about 15° C. to about 35° C., preferably at about room temperature, more preferably at about 20° C. to about 25° C. Preferably, ethanol is removed by concentration of the solution, preferably by evaporation of the solution Preferably, evaporation is done under reduced pressure. Preferably, ethanol is removed to dryness.
The present invention also encompasses a crystalline form of Dolasetron mesylate, designated Form V, characterized by a powder XRD pattern with peaks at about 13.0, 18.6 and 29.4±0.2 degrees 2-theta. Form V may be further characterized by a powder XRD with peaks at about 12.6, 17.3, 19.5, 20.1, 22.4, 24.0, and 28.2±0.2 degrees 2-theta. Form V may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form V of Dolasetron Mesylate comprises less than about 10% of any other form of Dolasetron Mesylate, measured by XRD. Preferably, the said crystalline form V of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention encompasses a process for the preparation of Form V of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from acetone
The crystallization comprises providing a solution of Dolasetron mesylate in acetone and precipitating the crystalline form to obtain a suspension.
Preferably, the solution is provided by combining Dolasetron mesylate and acetone, and heating the mixture. The starting Dolasetron mesylate can be any form of Dolasetron mesylate, preferably, Dolasetron mesylate monohydrate. Preferably, heating the mixture is to a temperature of about 45° C. to about 60° C., preferably at about 55° C. to about 60° C.
Precipitation is preferably carried out by concentrating the solution to obtain a suspension. Further, the suspension is preferably cooled to increase the yield of the precipitated crystalline form. Preferably, cooling is to a temperature of about 0° C. to about 10° C., more preferably of about 2° C. to about 8° C.
Preferably, cooling to a temperature of about 0° C. to about 10° C. is carried out over a period of about 8 to about 24 hours, more preferably of about 10 to about 16 hours.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention further encompasses a crystalline form of Dolasetron mesylate, designated Form VI, characterized by a powder XRD pattern with peaks at about 9.9, 15.2, and 16.0±0.2 degrees 2-theta. Form VI may be further characterized by a powder XRD with peaks at about 17.3, 18.1, 19.8, 20.6, 21.4, 24.3, and 28.2±0.2 degrees 2-theta. Form VI may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form VI of Dolasetron Mesylate may be with less than about 10% of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form VI of Dolasetron Mesylate may be with less than about 10%, preferably, with less than about 5% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention encompasses a process for the preparation of Form VI of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a mixture comprising methanol as a solvent and methyltertbutyl ether as an anti-solvent.
The crystallization comprises providing a solution of Dolasetron mesylate in methanol, and admixing the solution with methyltertbutyl ether to obtain a suspension comprising of the said crystalline form.
Preferably, the solution of Dolasetron mesylate is provided by combining Dolasetron mesylate and methanol, and heating the mixture. The starting Dolasetron mesylate can be any form of Dolasetron mesylate, preferably, Dolasetron mesylate monohydrate. Preferably, heating the mixture is to a temperature of about 60° C. to about reflux, preferably to about 62° C. to about 67° C.
Preferably, methyltertbutyl ether is added to the solution, to obtain a mixture containing of a sticky precipitate. Preferably, the mixture is cooled to a temperature of about 0° C. to about 10° C., more preferably to about 2° C. to about 8° C. Preferably, cooling to a temperature of about 0° C. to about 10° C. is carried out over a period of about 1 to about 5 days, more preferably of about 2 to about 4 days, most preferably of about 4 days.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention further encompasses a crystalline form of Dolasetron mesylate, designated Form VIII, characterized by a powder XRD pattern with peaks at about 10.1, 16.3, and 22.6±0.2 degrees 2-theta. Form VIII may be further characterized by a powder XRD with peaks at about 12.5, 17.0, 20.1, 20.8, 25.9, 28.5, and 29.9±0.2 degrees 2-theta. Form VIII may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form VIII of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, with less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form VIII of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention also encompasses a process for the preparation of Form VIII of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a dimethylcarbonate.
Preferably, crystallization is done by a process comprising providing a solution of Dolasetron mesylate in dimethylcarbonate, and precipitating the said crystalline form to obtain a suspension.
Preferably, the solution is provided by combining Dolasetron mesylate and dimethylcarbonate, and heating the mixture. The starting Dolasetron mesylate maybe any form of Dolasetron mesylate, preferably, Dolasetron mesylate monohydrate. Preferably, heating mixture is to a temperature of about 85° C. to about reflux, preferably of about 88° C. to about 93° C. The dissolution may not be complete, thus a mixture may be obtained.
Preferably, precipitation is done by cooling the said solution. Preferably, cooling is to a temperature of about −10° C. to about 10° C., preferably to about 5° C. to about 10° C. Preferably, cooling is carried out over a period of about 8 to about 24 hours, more preferably of about 10 to about 16 hours.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention encompasses a crystalline form of Dolasetron mesylate, designated Form IX, characterized by a powder XRD pattern with peaks at about 9.8, 18.3, and 27.9±0.2 degrees 2-theta. Form IX may be further characterized by a powder XRD with peaks at about 12.7, 19.5, 20.3, 20.6, 22.1, 29.4, and 31.9±0.2 degrees 2-theta. Form IX may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form IX of Dolasetron Mesylate comprises less than about 30% of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form IX of Dolasetron Mesylate comprises less than about 30% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention further encompasses a process for the preparation of Form IX of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a refluxed solution of Dolasetron mesylate in nitromethane; wherein the solution is refluxed at a about 98° C. to about 102° C.
The crystallization is preferably done by a process comprising providing a solution of Dolasetron mesylate in nitromethane, at reflux temperature, and precipitating the said form to obtain a suspension.
The solution of Dolasetron mesylate in nitromethane is provided by combining Dolasetron mesylate and nitromethane and heating the mixture. The starting Dolasetron mesylate maybe any form of Dolasetron mesylate, preferably, the Dolasetron monohydrate.
Precipitation of the said form is preferably done by cooling the solution. Preferably, cooling is to a temperature of about 0° C. to about 10° C., more preferably to about 2° C. to about 8° C. Preferably, cooling is done over a period of about 8 to about 24 hours, more preferably for about 10 to about 16 hours.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention also encompasses a crystalline form of Dolasetron mesylate, designated Form X, characterized by a powder XRD pattern with peaks at about 9.4, 17.7 and 27.1±0.2 degrees 2-theta. Form X may be further characterized by a powder XRD with peaks at about 12.5, 16.5, 17.1, 18.8, 19.2, 20.4, and 21.2±0.2 degrees 2-theta. Form X may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form X of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form X of Dolasetron Mesylate comprises less than about 10%, preferably, with less than about 5%, more preferably, with less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention further encompasses a process for the preparation of Form X of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a C3-6 ether, preferably 1,4-dioxane.
The crystallization is preferably done by a process comprising providing a solution of Dolasetron mesylate in 1,4-dioxane, precipitating the said form to obtain a suspension.
The solution of Dolasetron mesylate is provided by combining Dolasetron mesylate and 1,4-dioxane, and heating the mixture. The starting Dolasetron mesylate maybe any form of Dolasetron mesylate, preferably, the starting Dolasetron mesylate monohydrate. Preferably, heating of the mixture is to a temperature of about 95° C. to about reflux, preferably of about 98° C. to about 102° C. Preferably, the 1,4-dioxane solvent contains about 1% to about 10% of water, more preferably, about 1% to about 5% of water, by weight.
The precipitation of the said form is preferably done by cooling the said solution. Preferably, cooling is to a temperature of about 0° C. to about 10° C., more preferably of about 2° C. to about 8° C. Preferably, cooling is conducted over a period of about 1 to about 4 days, more preferably for about 2 to about 3 days, most preferably for about 3 days.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention also encompasses a crystalline form of Dolasetron mesylate, designated Form XI, characterized by a powder XRD pattern with peaks at about 14.1, 14.9, 16.2 and 18.2±0.2 degrees 2-theta. Form XI may be further characterized by a powder XRD with peaks at about 12.2, 12.9, 19.0, 20.9, 22.5, 23.6, 27.9, and 29.1±0.2 degrees 2-theta. Form XI may also be also substantially identified by the PXRD pattern as depicted in
The said crystalline form XI of Dolasetron Mesylate comprises less than about 30% of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form XI of Dolasetron Mesylate comprises less than about 30% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention encompasses a process for the preparation of Form XI of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a mixture comprising a C2-6 ester, preferably ethyllactate as a solvent, and methyltertbutyl ether as an anti-solvent.
The crystallization is preferably done by a process comprising providing a solution of Dolasetron mesylate in ethyllactate, and admixing the solution with methyltertbutyl ether to obtain a suspension comprising of the said crystalline form.
Preferably, the solution of Dolasetron mesylate is provided by combining Dolasetron mesylate and ethyllactate, and heating the mixture. The starting Dolasetron mesylate can be any form of Dolasetron mesylate, preferably, Dolasetron mesylate monohydrate. Preferably, heating the mixture is to a temperature of about 40° C. to about 60° C., more preferably of about 40° C. to about 50° C.
Preferably, methyltertbutyl ether is added to the solution, to obtain a mixture comprising a sticky precipitate. Preferably, the mixture is cooled at a temperature of about 0° C. to about 110° C., more preferably of about 2° C. to about 8° C. Preferably, cooling is conducted for about 1 to about 5 days, more preferably for about 1 to about 4 days, most preferably for about 4 days, to obtain a solid.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention further encompasses a crystalline form of Dolasetron mesylate, designated Form XII, characterized by a powder XRD pattern with peaks at about 14.7, 17.6 and 18.2±0.2 degrees 2-theta. Form XII may be further characterized by a powder XRD with peaks at about 13.3, 14.0, 15.8, 20.5, 24.0, 24.9, and 27.1±0.2 degrees 2-theta. Form XII may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form XII of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form XII of Dolasetron Mesylate comprise less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention also encompasses a process for the preparation of Form XII of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a C6-8 aromatic hydrocarbon, preferably toluene.
The crystallization is preferably done by a process comprising providing a solution of Dolasetron mesylate in toluene, and precipitating the said crystalline form to obtain a suspension.
The solution is provided by combining Dolasetron mesylate and toluene, and heating the mixture. The starting Dolasetron mesylate can be any form of Dolasetron mesylate, preferably, the starting Dolasetron mesylate is Dolasetron mesylate monohydrate. Preferably, heating is to a temperature of about 80° C. to about reflux, preferably to about 108° C. to about 112° C. Preferably, heating the mixture is done for about 0.5 to about 2 hours. Preferably, the heating is done while the process is conducted with removal of water, preferably by the use of a water trap.
Precipitation of Dolasetron mesylate is preferably done by cooling the said solution. Preferably, the solution is cooled to about 15° C. to about 35° C., more preferably to about room temperature, most preferably, to a temperature of about 20° C. to about 25° C. Preferably, cooling is conducted for about 8 to about 24 hours, more preferably for about 10 to about 16 hours.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention further provides an additional process for preparing the said Form XII by heating a Dolasetron mesylate polymorph selected from the group consisting of: crystalline Form V of Dolasetron mesylate, crystalline form VIII of Dolasetron mesylate, and mixtures thereof.
Preferably, the starting Form of Dolasetron mesylate is heated to a temperature of about 150° C. to about 220° C., more preferably, to about 160° C. Preferably, the heating is done for about 30 to about 70 minutes, more preferably, for about 60 minutes.
The present invention encompasses a crystalline form of Dolasetron mesylate, designated Form XIII, characterized by a powder XRD pattern with peaks at about 9.1, 15.0 and 18.1±0.2 degrees 2-theta. Form XIII may be further characterized by a powder XRD with peaks at about 12.5, 16.8, 19.4, 21.0, 22.3, 23.2 and 27.2±0.2 degrees 2-theta. Form XIII may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form XIII of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form XIII of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention also encompasses a process for the preparation of Form XIII of Dolasetron mesylate by a process comprising crystallizing Dolasetron mesylate from a solution of Dolasetron mesylate in nitromethane; wherein the solution is provided at about 15° C. to about 35° C., more preferably to about room temperature.
The crystallization comprises providing a solution of Dolasetron mesylate in nitromethane at about room temperature, and precipitating the said form to obtain a suspension. The starting Dolasetron mesylate can be any form of Dolasetron mesylate, preferably, the Dolasetron mesylate monohydrate. Preferably, the dissolution is done at a temperature of about 20° C. to about 25° C.
The precipitation is preferably done by cooling the solution. Preferably, the solution is cooled to a temperature of about 0° C. to about 10° C., more preferably to about 2° C. to about 8° C. Preferably, cooling is conducted over a period of about 8 to about 24 hours, more preferably for about 10 to about 16 hours.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension.
The present invention encompasses a crystalline form of Dolasetron mesylate, designated Form XIV, characterized by a powder XRD pattern with peaks at about 17.4, 17.9 and 22.1±0.2 degrees 2-theta. Form XIV may be further characterized by a powder XRD with peaks at about 12.6, 16.6, 19.3, 20.3, 20.7, 27.8 and 29.2±0.2 degrees 2-theta. Form XIV may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form XIV of Dolasetron Mesylate comprises less than about 10% of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form XIV of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention further encompasses a process for the preparation of Form XIV of Dolasetron mesylate by drying form XIII.
Preferably, Form XIII is dried at a temperature of about 35° C. to about 55° C., preferably of about 35° C. to about 45° C. Preferably, the drying is conducted under reduced pressure. Preferably, drying is done for about 8 to about 24 hours, more preferably for about 10 to about 16 hours.
The present invention also encompasses a crystalline form of Dolasetron mesylate, designated Form XV, characterized by a powder XRD pattern with peaks at about 12.2, 14.1, 14.8, 16.3 and 22.2±0.2 degrees 2-theta. Form XV may be further characterized by a powder XRD pattern with peaks at about 9.3, 18.6, 20.2, 20.6, 21.1, 22.2 and 28.2±0.2 degrees 2-theta. Form XV may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form XV of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, less than about 1%, of any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form XV of Dolasetron Mesylate comprises less than about 10%, preferably, less than about 5%, more preferably, with less than about 1%, of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention encompasses a process for preparing crystalline Form XV of Dolasetron mesylate by exposing crystalline Form III of Dolasetron mesylate to humidity.
Preferably, crystalline Form III is exposed to 100% relative humidity. Preferably, the exposure is done at a temperature of about 15° C. to about 35° C., more preferably, at a temperature of about 22° C. to about 25° C. Preferably, the exposure is done for about 2 to about 14 days, more preferably, for about 3 to about 10 days, most preferably, for about 3 days.
The present invention further encompasses a crystalline form of Dolasetron mesylate, designated Form XVI, characterized by a powder XRD pattern with peaks at about 12.1, 14.0, 14.8 15.1 and 22.1±0.2 degrees 2-theta. Form XVI of Dolasetron mesylate may be further characterized by a powder XRD pattern with peaks at about 9.3, 19.6, 20.0, 20.5, 21.0, 22.1 and 28.7±0.2 degrees 2-theta. Form XVI may also be substantially identified by the PXRD pattern as depicted in
The said crystalline form XVI of Dolasetron Mesylate comprises less than about 10% any other form of Dolasetron Mesylate, as measured by XRD. Preferably, the said crystalline form XVI of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
The present invention also encompasses a process for preparing crystalline Form XVI of Dolasetron mesylate by exposing crystalline Form XII of Dolasetron mesylate to humidity.
Preferably, crystalline Form XII is exposed to 100% relative humidity. Preferably, the exposure is done at a temperature of about 20° C. to about 30° C., more preferably, at a temperature of about 22° C. to about 25° C. Preferably, the exposure is done for about 2 to about 14 days, more preferably, for about 3 to about 10 days, most preferably, for about 3 days.
The present invention also encompasses a process for preparing crystalline form of Dolasetron mesylate, designated form II, comprising combining Dolasetron base, methanesulfonic acid, and a solvent mixture of acetone and water to obtain Dolasetron mesylate; and crystallizing it from the said solvent mixture. Preferably, the Dolasetron mesylate is provided, at about room temperature, more preferably, at about 20° C. to about 25° C.
Preferably, the ratio of acetone and water in the solvent mixture is of about 99:1 to about 80:20, respectively, more preferably, of about 99:5 to about 99:1, respectively. Preferably, the addition of methane sulfonic acid transforms the suspension into a solution.
The crystallization is done by obtaining a suspension comprising the said crystalline form. Preferably, the suspension is formed after a few minutes after the addition of methane sulfonic acid. Further, the suspension is preferably cooled to increase the yield of the crystallized product. Preferably, the suspension is cooled to a temperature of about 0° C. to about 10° C., more preferably to about 2° C. to about 8° C. Preferably, cooling is conducted for about 8 to about 24 hours, more preferably for about 10 to about 16 hours.
The process may further comprise recovering the said crystalline form. The recovery may be done by any method known to a skilled artisan. The recovering of the precipitate may be done by filtering the suspension, and drying the filtered crystalline form.
The present invention also provides preparing crystalline form II of Dolasetron mesylate by heating amorphous Dolasetron mesylate Form VII at about 90° C. for about 15 minutes to 30 minutes.
The present invention also provides an alcoholate solvate of Dolasetron mesylate. Preferably, the alcoholate solvate is an ethanol solvate or methanol solvate of Dolasetron mesylate.
The present invention provides an anhydrous Dolasetron mesylate.
The present invention also provides a ketone solvate of Dolasetron mesylate. Preferably, the ketone solvate is an acetone solvate of Dolasetron mesylate.
The present invention provides a carbonate solvate of Dolasetron mesylate. Preferably the carbonate solvate is a methyl carbonate solvate of Dolasetron mesylate.
The present invention also provides an ether solvate of Dolasetron mesylate. Preferably, the ether solvate is a 1,4 dioxane solvate of Dolasetron mesylate.
The present invention provides an ester solvate of Dolasetron mesylate. Preferably, the ester solvate is an ethyl lactate solvate of Dolasetron mesylate.
The present invention also provides a nitromethane solvate of Dolasetron mesylate.
The present invention also provides a hydrated Dolasetron mesylate. Preferably, the hydrated Dolasetron mesylate is a monohydrate or dihydrate of Dolasetron mesylate.
The present invention comprises a pharmaceutical composition comprising any one of the designated forms of Dolasetron Mesylate, Forms I, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, and at least one pharmaceutically acceptable excipient.
The present invention further comprises a pharmaceutical composition comprising any one of the designated forms of Dolasetron Mesylate, Forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, prepared according to the processes of the present invention, and at least one pharmaceutically acceptable excipient.
The present invention also encompasses a process for preparing a pharmaceutical formulation comprising combining any one of the designated forms of Dolasetron Mesylate, Forms I, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, with at least one pharmaceutically acceptable excipient.
The present invention also encompasses a process for preparing a pharmaceutical formulation comprising combining any one of the designated forms of Dolasetron Mesylate, Forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, prepared according to the processes of the present invention, with at least one pharmaceutically acceptable excipient.
The present invention also encompasses the use of any one of the designated forms of Dolasetron Mesylate, Forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, for the manufacture of a pharmaceutical composition.
The pharmaceutical composition of the present invention can be administered in various preparations depending on the age, sex, and symptoms of the patient. The pharmaceutical compositions can be administered, for example, as tablets, pills, powders, liquids such as suspensions and emulsions, granules, capsules, suppositories, injection preparations (suspensions), and the like.
Pharmaceutical compositions of the present invention can optionally be mixed with other forms of Dolasetron Mesylate and/or other active ingredients. In addition, pharmaceutical compositions of the present invention can contain inactive ingredients such as diluents, carriers, fillers, bulking agents, binders, disintegrants, disintegration inhibitors, absorption accelerators, wetting agents, lubricants, glidants, surface active agents, flavoring agents, and the like.
Diluents increase the bulk of a solid pharmaceutical composition and can make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), microfine cellulose, lactose, starch, pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, or talc.
Carriers for use in the pharmaceutical compositions may include, but are not limited to, lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, or silicic acid.
Binders help bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include for example acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, or starch.
Disintegrants can increase dissolution. Disintegrants include, for example, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch.
Disintegration inhibitors may include, but are not limited to, white sugar, stearin, coconut butter, hydrogenated oils, and the like.
Absorption accelerators may include, but are not limited to, quaternary ammonium base, sodium laurylsulfate, and the like.
Wetting agents may include, but are not limited to, glycerin, starch, and the like. Adsorbing agents used include, but are not limited to, starch, lactose, kaolin, bentonite, colloidal silicic acid, and the like.
A lubricant can be added to the composition to reduce adhesion and ease release of the product from a punch or dye during tableting. Lubricants include for example magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
Glidants can be added to improve the flowability of non-compacted solid composition and improve the accuracy of dosing. Excipients that can function as glidants include for example colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.
Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present invention include for example maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
Tablets can be further coated with commonly known coating materials such as sugar coated tablets, gelatin film coated tablets, tablets coated with enteric coatings, tablets coated with films, double layered tablets, and multi-layered tablets. Capsules can be coated with shell made, for example, from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
In liquid pharmaceutical compositions of the present invention, the Dolasetron Mesylate of the present invention is suspended, while maintaining its crystalline characteristics, and any other solid ingredients are dissolved or suspended in a liquid carrier, such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.
Liquid pharmaceutical compositions of the present invention can also contain viscosity enhancing agents to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include for example acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.
Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar can be added to improve the taste.
Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid can be added at safe levels to improve storage stability.
A liquid composition according to the present invention can also contain a buffer such as guconic acid, lacetic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate.
Selection of excipients and the amounts to use can be readily determined by an experienced formulation scientist in view of standard procedures and reference works known in the art.
A composition for tableting or capsule filing can be prepared by wet granulation. In wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, which causes the powders to clump up into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate can then be tableted or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.
A tableting composition can be prepared conventionally by dry blending. For instance, the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can be compressed subsequently into a tablet.
As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well-suited to direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
A capsule filling of the present invention can comprise any of the aforementioned blends and granulates that were described with reference to tableting, only they are not subjected to a final tableting step.
When shaping the pharmaceutical composition into pill form, any commonly known excipient used in the art can be used. For example, carriers include, but are not limited to, lactose, starch, coconut butter, hardened vegetable oils, kaolin, talc, and the like. Binders used include, but are not limited to, gum arabic powder, tragacanth gum powder, gelatin, ethanol, and the like. Disintegrating agents used include, but are not limited to, agar, laminalia, and the like.
For the purpose of shaping the pharmaceutical composition in the form of suppositories, any commonly known excipient used in the art can be used. For example, excipients include, but are not limited to, polyethylene glycols, coconut butter, higher alcohols, esters of higher alcohols, gelatin, semisynthesized glycerides, and the like.
When preparing injectable pharmaceutical compositions, suspensions are sterilized and are preferably made isotonic to blood. Injection preparations may use carriers commonly known in the art. For example, carriers for injectable preparations include, but are not limited to, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and fatty acid esters of polyoxyethylene sorbitan. One of ordinary skill in the art can easily determine with little or no experimentation the amount of sodium chloride, glucose, or glycerin necessary to make the injectable preparation isotonic. Additional ingredients, such as dissolving agents, buffer agents, and analgesic agents may be added. If necessary, coloring agents, preservatives, perfumes, seasoning agents, sweetening agents, and other medicines may also be added to the desired preparations during the treatment of schizophrenia.
The amount of Dolasetron Mesylate of the present invention contained in a pharmaceutical composition according to the present invention is not specifically restricted; however, the dose should be sufficient to treat, ameliorate, or reduce the condition.
The present invention also provides a method of treating a patient comprising administering a therapeutically effective amount of any one of crystalline Dolasetron mesylate forms I, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, or mixtures thereof, to a patient in need thereof. The patient may be a patient in need of an antiemetic or antinauseant agent while undergoing chemo- and/or radiotherapy.
Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the process and compositions of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLESInstruments
XRD
XRD diffraction was performed on X-Ray powder diffractometer, ARL, θ-θ goniometer, Cu-tube, solid state detector with Peltier cooling. Sample holder: A round standard aluminum sample holder with round zero background was used.
Scanning parameters: Range: 2-40 deg.2θ, Continuous Scan, Rate: 3 deg./min.
Thermal Analysis
DSC thermogram was performed on DSC822e, Mettler Toledo
Sample weight: 3-5 mg
Heating rate: 10° C./min
Number of holes in the crucible: 3
Nitrogen flow rate: 40 ml/min.
TGA
TGA thermogram was performed on Mettler TGA/SDTA 851 using standard Alumina pan.
Sample weight: 7-15 mg,
Heating rate: 10° C./min
Nitrogen flow rate: 50 ml/min.
Example 1 Preparation of Crystalline Form I of Dolasetron MesylateDLS base (1.70 g, 5.24 mmol) was dissolved in 96% of ethanol (100 ml) at room temperature. Methanesulfonic acid (0.34 ml, 1 equiv.) was added and the solution was evaporated to 22 g. Acetone (100 ml), then tert-butylmethyl ether (100 ml) were added to the residue. The solution was put into the fridge overnight. The formed crystals were filtered off, washed with acetone, dried at room temperature on air and obtained 1.80 g (82%). The dry substance obtained was crystalline.
Comparative Example 2 Preparation of Dolasetron Mesylate Monohydrate, Form II, according to EP 0339669To a solution of DLS base (2.87 g, 8.85 mmol) in acetone (30 ml) was added dropwise methanesulfonic acid (0.62 ml) during about 5 minutes at 20-25° C. After a few minutes, DLS-MsOH began to separate and solidify. The mixture was stirred at 0-5° C. for 2 hours and filtered. The solid material washed with acetone (2×5 ml) and dried in vacuo at 35-40° C. overnight to obtain 3.38 g (91%) of Dolasetron mesylate.
The dried DLS-MsOH (2.7 g, 6.42 mmol) was recrystallized by dissolving in hot 5% aqueous isopropanol (41 ml) and adding ether (7 ml) to the cloud point at about 30° C. The stirring was continued at 20-25° C. for 6 hours, then the precipitated material was filtered, washed with ether (2×5 ml) and dried at 20-25° C. to obtain 2.0 g (71%) of Dolasetron mesylate monohydrate characterized by a powder XRD pattern with peaks at 9.9, 12.1, 12.9, 15.1, 17.1, 19.0, 19.7, 20.0 and 22.4±0.2 degrees two-theta.
Example 3 Preparation of Dolasetron Mesylate Form IIMethanesulfonic acid (2.85 ml, 1 equiv) was added to a stirred suspension of Dolasetron base (14.24 g, 43.9 mmol) in a mixture of acetone-water 95:5 (100 ml). The solid dissolved immediately, and after some minutes the salt precipitated in crystalline form. The mixture was put into fridge, after 4 hours the salt was filtered off, washed with the same solvent mixture (2×15 ml), dried overnight in an air-ventilated oven at 40° C. The yield was 15.63 g (81%).
Example 4 Preparation of Amorphous Dolasetron Mesylate Form VIIDolasetron mesylate monohydrate (0.50 g) was dissolved in methanol (80 ml) at room temperature. The solution was evaporated to dryness under reduced pressure.
Example 5 Preparation of Dolasetron Mesylate Form IIIDolasetron mesylate monohydrate (0.50 g) was dissolved in tert-butanol (90 ml) under reflux. The solution was allowed to stand at room temperature for 3 days. The precipitated crystals are filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form III.
Example 6 Preparation of Dolasetron Mesylate Form IVDolasetron mesylate monohydrate (0.50 g) was dissolved in abs. ethanol (400 ml) at room temperature. The solution was evaporated to dryness under reduced pressure.
Example 7 Preparation of Dolasetron Mesylate Form VDolasetron mesylate monohydrate (0.50 g) was dissolved in acetone (200 ml) under reflux. The solution was evaporated to small volume until starting of crystallization (6 g) under reduced pressure. The mixture was put into fridge overnight. The precipitated crystals were filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form V.
Example 8 Preparation of Dolasetron Mesylate Form VIDolasetron mesylate monohydrate (0.50 g) was dissolved in methanol (5 ml) under reflux. Methyl tert-butyl ether (20 ml) was added to the solution, the material precipitated in sticky form. The mixture was put into fridge for 4 days. The sticky material solidified, the crystals were filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form VI.
Example 9 Preparation of Dolasetron Mesylate Form VIIIDolasetron mesylate monohydrate (0.50 g) was dissolved in dimethyl carbonate (200 ml) under reflux. The solid did not dissolve totally. The mixture was put into the fridge overnight. The precipitated crystals were filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form VIII.
Example 10 Preparation of Dolasetron Mesylate Form IXDolasetron mesylate monohydrate (0.50 g) was dissolved in nitromethane (5 ml) under reflux. The solution was put into fridge overnight. The precipitated crystals were filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form IX.
Example 11 Preparation of Dolasetron mesylate Form XDolasetron mesylate monohydrate (0.50 g) was dissolved in a mixture of 1,4-dioxane and water 95:5 (60 ml) under reflux. The solution was allowed to stand at room temperature for 3 days. The precipitated crystals were filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form X.
Example 12 Preparation of Dolasetron Mesylate Form XIDolasetron mesylate monohydrate (0.50 g) was dissolved in ethyl lactate (5 ml) at 40-50° C. Methyl tert-butyl ether (12 ml) was added to the solution, the material precipitated in sticky form. The mixture was put into fridge for 4 days. The sticky material solidified, the crystals were filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form XI.
Example 13 Preparation of Dolasetron Mesylate Form XIIDolasetron mesylate monohydrate (0.50 g) was refluxed in toluene (120 ml) with water trap for 1 hour. The mixture was allowed to stand at room temperature overnight. The precipitated crystals are filtered off, dried overnight at 40° C. under reduced pressure. Wet and dry samples were form XII.
Example 14 Preparation of Dolasetron mesylate Form XIIIDolasetron mesylate monohydrate (0.50 g) was dissolved in nitromethane (20 ml) at room temperature. The solution was put into fridge overnight. The precipitated crystals were filtered off, leading to form XIII.
Example 15 Preparation of Dolasetron mesylate Form XIVForm XIII obtained in example 14 was dried overnight at 40° C. under reduced pressure to give form XIV.
Example 16 Preparation of Dolasetron mesylate Form XV200 mg of Form III of Dolasetron mesylate was exposed of in a glass bottle to 100% relative humidity for three days, at 25° C.
Example 17 Preparation of Dolasetron Mesylate Form XVI200 mg of Dolasetron mesylate form XII was exposed in a glass bottle to 100% relative humidity for three days at 25° C.
Example 18 Heat Transformations
Claims
1. A crystalline Dolasetron Mesylate characterized by a powder XRD pattern with peaks at about 12.6, 18.2, and 19.6±0.2 degrees two-theta.
2. The crystalline Dolasetron mesylate of claim 1, wherein the crystalline form is further characterized by an X-ray powder diffraction pattern with peaks at about 9.9, 13.8, 16.6, 21.1, 23.3, 27.9, and 29.6±0.2 degrees two-theta.
3-10. (canceled)
11. The crystalline Dolasetron mesylate of claim 1, wherein the crystalline form of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
12-17. (canceled)
18. An amorphous Dolasetron mesylate.
19-22. (canceled)
23. The amorphous Dolasetron mesylate of claim 18 wherein the amorphous form of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
24-28. (canceled)
29. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 14.0, 14.8, 16.1, and 18.2±0.2 degrees 2-theta.
30. The crystalline Dolasetron mesylate of claim 29, wherein the crystalline form is further characterized by a powder XRD with peaks at about 9.2, 12.2, 20.9, 27.9, 29.0, and 29.6±0.2 degrees 2-theta.
31-40. (canceled)
41. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 13.8, 16.5, 22.1, and 25.2±0.2 degrees 2-theta.
42. The crystalline Dolasetron mesylate of claim 41, wherein the crystalline form is further characterized by a powder XRD with peaks at about 9.7, 12.5, 18.0, 19.4, 20.7, and 27.5±0.2 degrees 2-theta.
43-48. (canceled)
49. The crystalline Dolasetron mesylate of claim 41, wherein the crystalline comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
50. (canceled)
51. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 13.0, 18.6 and 29.4±0.2 degrees 2-theta.
52. The crystalline Dolasetron mesylate of claim 51, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.6, 17.3, 19.5, 20.1, 22.4, 24.0, and 28.2±0.2 degrees 2-theta.
53-58. (canceled)
59. The crystalline Dolasetron mesylate of claim 51, wherein the crystalline form comprises less than about 10%, preferably, with less than about 5% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
60-64. (canceled)
65. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.9, 15.2, and 16.0±0.2 degrees 2-theta.
66. The crystalline Dolasetron mesylate of claim 65, wherein the crystalline form is further characterized by a powder XRD with peaks at about 17.3, 18.1, 19.8, 20.6, 21.4, 24.3, and 28.2±0.2 degrees 2-theta.
67-72. (canceled)
73. The crystalline Dolasetron mesylate of claim 65, wherein the crystalline form comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
74-79. (canceled)
80. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 10.1, 16.3, and 22.6±0.2 degrees 2-theta.
81. The crystalline Dolasetron mesylate of claim 80, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.5, 17.0, 20.1, 20.8, 25.9, 28.5, and 29.9±0.2 degrees 2-theta.
82-87. (canceled)
88. The crystalline Dolasetron mesylate of claim 80, wherein the crystalline form comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
89-93. (canceled)
94. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.8, 18.3, and 27.9±0.2 degrees 2-theta.
95. The crystalline Dolasetron mesylate of claim 94, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.7, 19.5, 20.3, 20.6, 22.1, 29.4, and 31.9±0.2 degrees 2-theta.
96-100. (canceled)
101. The crystalline Dolasetron mesylate of claim 94, wherein the crystalline form of Dolasetron Mesylate comprises less than about 30% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
102-105. (canceled)
106. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.4, 17.7 and 27.1±0.2 degrees 2-theta.
107. The crystalline Dolasetron mesylate of claim 106, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.5, 16.5, 17.1, 18.8, 19.2, 20.4, and 21.2±0.2 degrees 2-theta.
108-113. (canceled)
114. The crystalline form of Dolasetron Mesylate of claim 106, wherein the crystalline form comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
115-119. (canceled)
120. A crystalline Dolasetron mesylate, characterized by a powder XRD pattern with peaks at about 14.1, 14.9, 16.2 and 18.2±0.2 degrees 2-theta.
121. The crystalline Dolasetron mesylate of claim 120, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.2, 12.9, 19.0, 20.9, 22.5, 23.6, 27.9, and 29.1±0.2 degrees 2-theta.
122-127. (canceled)
128. The crystalline Dolasetron mesylate of claim 120, wherein the crystalline Dolasetron Mesylate comprises less than about 30% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
129-134. (canceled)
135. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 14.7, 17.6 and 18.2±0.2 degrees 2-theta.
136. The crystalline Dolasetron mesylate of claim 135, wherein the crystalline form is further characterized by a powder XRD with peaks at about 13.3, 14.0, 15.8, 20.5, 24.0, 24.9, and 27.1±0.2 degrees 2-theta.
137-141. (canceled)
142. The crystalline Dolasetron mesylate of claim 135, wherein the crystalline form of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
143-149. (canceled)
150. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 9.1, 15.0 and 18.1±0.2 degrees 2-theta.
151. The crystalline Dolasetron mesylate of claim 150, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.5, 16.8, 19.4, 21.0, 22.3, 23.2 and 27.2±0.2 degrees 2-theta.
152-153. (canceled)
154. The crystalline Dolasetron mesylate of claim 150, wherein the crystalline form of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
155-157. (canceled)
158. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 17.4, 17.9 and 22.1±0.2 degrees 2-theta.
159. The crystalline Dolasetron mesylate of claim 158, wherein the crystalline form is further characterized by a powder XRD with peaks at about 12.6, 16.6, 19.3, 20.3, 20.7, 27.8 and 29.2±0.2 degrees 2-theta.
160-164. (canceled)
165. The crystalline Dolasetron mesylate of claim 158, wherein the crystalline form of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
166-167. (canceled)
168. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 12.2, 14.1, 14.8, 16.3 and 22.2±0.2 degrees 2-theta.
169. The crystalline Dolasetron mesylate of claim 168, wherein the crystalline form is further characterized by a powder XRD pattern with peaks at about 9.3, 18.6, 20.2, 20.6, 21.1, 22.2 and 28.2±0.2 degrees 2-theta.
170-174. (canceled)
175. The crystalline Dolasetron mesylate of claim 168, wherein the crystalline form of Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
176-177. (canceled)
178. A crystalline Dolasetron mesylate characterized by a powder XRD pattern with peaks at about 12.1, 14.0, 14.8 15.1 and 22.1±0.2 degrees 2-theta.
179. The crystalline Dolasetron mesylate of claim 178, wherein the crystalline form is further characterized by a powder XRD pattern with peaks at about 9.3, 19.6, 20.0, 20.5, 21.0, 22.1 and 28.7±0.2 degrees 2-theta.
180-184. (canceled)
185. The crystalline Dolasetron mesylate of claim 178, wherein the said crystalline Dolasetron Mesylate comprises less than about 10% of crystalline form II of Dolasetron Mesylate, as measured by XRD.
186-187. (canceled)
188. A method for preparing crystalline Dolasetron mesylate, designated form II, comprising combining Dolasetron base, methanesulfonic acid, and a solvent mixture comprising acetone, and water to obtain Dolasetron mesylate; and crystallizing it from the said solvent mixture.
189. The method of claim 188, wherein Dolasetron mesylate is provided by combining Dolasetron base in a solvent mixture comprising acetone and water to obtain a suspension, and admixing the suspension with methanesulfonic acid to obtain a solution comprising of Dolasetron mesylate.
190. The method of claim 189, wherein the crystallization is done by obtaining a suspension comprising the said crystalline form.
191. The method of claim 190, wherein the suspension is formed after a few minutes after the addition of methane sulfonic acid.
192. A crystalline anhydrous Dolasetron mesylate.
193. A crystalline solvate of Dolasetron mesylate selected from the group consisting of a ketone solvate, a carbonate solvate, an ether solvate, an ester solvate, and a nitromethane solvate.
194. The crystalline solvate of claim 193, wherein the solvate is a ketone solvate of Dolasetron mesylate.
195. The crystalline solvate of claim 193, wherein the solvate is a carbonate solvate of Dolasetron mesylate.
196. The crystalline carbonate solvate of claim 195, wherein the carbonate solvate is a methyl carbonate solvate of Dolasetron mesylate.
197. The crystalline solvate of claim 193, wherein the solvate is an ether solvate of Dolasetron mesylate.
198. The crystalline ether solvate of claim 197, wherein the ether solvate is a 1,4 dioxane solvate of Dolasetron mesylate.
199. The crystalline solvate of claim 193, wherein the solvate is an ester solvate of Dolasetron mesylate.
200. The crystalline ester solvate of claim 199, wherein the ester solvate is an ethyl lactate solvate of Dolasetron mesylate.
201. The crystalline solvate of claim 193, wherein the solvate is a nitromethane solvate of Dolasetron mesylate.
202. A crystalline hydrated Dolasetron mesylate.
203. The crystalline hydrated Dolasetron mesylate of claim 202, wherein the hydrated Dolasetron mesylate is a monohydrate or dihydrate of Dolasetron mesylate.
204. A pharmaceutical composition comprising a crystalline Dolasetron mesylate polymorph selected from the group consisting of: form I, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, and at least one pharmaceutically acceptable excipient.
205. A method for preparing a pharmaceutical formulation comprising combining a crystalline Dolasetron Mesylate polymorph selected from the group consisting of: Form I, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, with at least one pharmaceutically acceptable excipient.
206. (canceled)
207. A method of treating a patient comprising administering a therapeutically effective amount of any one of crystalline Dolasetron mesylate forms I, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, and XVI, or mixtures thereof, to a patient in need thereof.
208. The crystalline solvate of claim 194, wherein the ketone solvate is an acetone solvate of Dolasetron mesylate.
Type: Application
Filed: Jan 5, 2007
Publication Date: Aug 30, 2007
Inventors: Janos Hajko (Debrecen), Tivadar Tamas (Debrecen), Adrienne Kovacsne-Mezei (Debrecen), Erika Molnarne (Debrecen), Csaba Peto (Debrecen), Csaba Szabo (Debrecen)
Application Number: 11/650,352
International Classification: A61K 31/4745 (20060101);
